Bristol-Myers Squibb (NYSE:BMY) Holdings Decreased by Mogy Joel R Investment Counsel Inc.

Mogy Joel R Investment Counsel Inc. cut its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.1% during the 1st quarter, HoldingsChannel.com reports. The firm owned 18,945 shares of the biopharmaceutical company’s stock after selling 215 shares during the period. Mogy Joel R Investment Counsel Inc.’s holdings in Bristol-Myers Squibb were worth $1,155,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in BMY. Allen Mooney & Barnes Investment Advisors LLC lifted its position in shares of Bristol-Myers Squibb by 1.2% in the 1st quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 33,199 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 406 shares during the last quarter. Davis Investment Partners LLC lifted its holdings in Bristol-Myers Squibb by 135.6% in the first quarter. Davis Investment Partners LLC now owns 17,224 shares of the biopharmaceutical company’s stock worth $1,050,000 after acquiring an additional 9,912 shares during the last quarter. Greenwood Capital Associates LLC lifted its holdings in Bristol-Myers Squibb by 5.1% in the first quarter. Greenwood Capital Associates LLC now owns 34,047 shares of the biopharmaceutical company’s stock worth $2,077,000 after acquiring an additional 1,648 shares during the last quarter. Simon Quick Advisors LLC boosted its stake in Bristol-Myers Squibb by 36.7% in the first quarter. Simon Quick Advisors LLC now owns 12,348 shares of the biopharmaceutical company’s stock valued at $753,000 after acquiring an additional 3,317 shares during the period. Finally, Capital Advisors Ltd. LLC grew its holdings in shares of Bristol-Myers Squibb by 19.0% during the first quarter. Capital Advisors Ltd. LLC now owns 3,165 shares of the biopharmaceutical company’s stock valued at $193,000 after purchasing an additional 506 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Samit Hirawat acquired 4,250 shares of the business’s stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.09% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wall Street Zen downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Cantor Fitzgerald reissued a “neutral” rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a research report on Friday, April 25th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Finally, UBS Group dropped their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research note on Friday, April 11th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $58.00.

Bristol-Myers Squibb Price Performance

NYSE:BMY opened at $50.13 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The business’s 50-day moving average price is $48.87 and its 200 day moving average price is $54.88. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The firm has a market cap of $102.01 billion, a P/E ratio of -11.34, a PEG ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion for the quarter, compared to analysts’ expectations of $10.77 billion. During the same quarter in the previous year, the company posted ($4.40) EPS. The business’s revenue was down 5.6% compared to the same quarter last year. As a group, sell-side analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.